We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Distinct Blood Signatures Found in COVID-19 Patients Could Significantly Improve Testing

By LabMedica International staff writers
Posted on 13 Jan 2021
Researchers have discovered distinct blood signatures present in patients with COVID-19 that could significantly improve testing and long-term monitoring of the disease.

The research team at the Australian National Phenome Centre (ANPC) at Murdoch University (Perth, Australia) applied advanced analytical chemistry methods to study the plasma of patients suffering from COVID-19 infection and found diagnostic markers that were not present in respiratory patients that tested negative for the virus. More...
Specifically, the research found that plasma lipoproteins – structures that transport fats around the body – in the blood of COVID-19 patients had changed dramatically during infection. They became closer to patterns typically found in patients with diabetes, atherosclerosis and cardiovascular disease.

The study involved the analysis of blood plasma samples collected from patients who presented COVID-19 disease symptoms and subsequently tested positive; healthy adults who had not exhibited COVID-19 disease symptoms; and patients with COVID-19 disease symptoms who tested negative. The samples were analyzed using state-of-the-art metabolic phenotyping technologies, which can reveal the molecular structures and quantitative bioanalysis for almost any type of biological liquid or solid. The analysis provided the unique biological ‘fingerprints’ of each sample, on which the research findings were based. The researchers believe that their work underlines the importance of long-term follow up studies on “recovered” COVID-19 patients, particularly those experiencing persistent effects, to assess their health status and take steps to mitigate any long-term effects of COVID-19 exposure.

“This work opens the door to a new type of test that does not depend on detection of the virus itself but that can help discriminate COVID-19 infections, especially when used in conjunction with conventional PCR testing,” explained Professor Jeremy Nicholson, Director of the ANPC and leader of the research. “This would increase the overall security of existing testing procedures, such as those used in quarantine situations, which may be key to future easing of State and National lock-down protocols especially with the advent of the new UK B.1.1.7 corona virus variant which is significantly more infectious and affects children more easily.”

Related Links:
Murdoch University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Flock Tipped Applicator
HydraFlock 6" Sterile Large Flock Swab w/Polystyrene Handle, 80mm Breakpoint
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.